Diagnostic performance of serum oncostatin M and MMP-9 in differentiating disease activity in Crohn's disease and ulcerative colitis
DOI:
https://doi.org/10.15584/ejcem.2026.2.16Keywords:
biomarker, Crohn’s disease, inflammatory bowel disease, matrix metalloproteinase-9, oncostatin M, ulcerative colitisAbstract
Introduction and aim. Inflammatory bowel disease (IBD) requires reliable noninvasive biomarkers for diagnosis and disease activity monitoring. Oncostatin M (OSM) and matrix metalloproteinase-9 (MMP-9) are implicated in intestinal inflammation and tissue remodeling, yet their combined diagnostic utility in IBD remains underexplored. The aim was to evaluate serum OSM and MMP-9 levels in Crohn's disease (CD) and ulcerative colitis (UC) patients compared to healthy controls, and to assess their correlation with disease activity and diagnostic performance.
Material and methods. This cross-sectional study included 105 participants (35 CD, 35 UC, 35 controls). Serum OSM and MMP-9 were measured by ELISA. Disease activity was evaluated using CDAI and the Total Mayo Score. ROC curve analysis evaluated diagnostic accuracy.
Results Both OSM and MMP-9 were significantly elevated in CD and UC compared to controls (p=0.016 and p=0.006, respectively), with progressive increases paralleling disease severity (p<0.001). For differentiating active from inactive CD, OSM demonstrated a high AUC of 0.951 (95% CI: 0.882–1.000) with 100% specificity (95% CI: 71.5%–100.0%). For active UC, MMP-9 achieved an AUC of 0.85 (95% CI: 0.724–0.976) with 95.4% sensitivity (95% CI: 78.9%–99.9%).
Conclusion. OSM and MMP-9 exhibit complementary diagnostic profiles, with OSM excelling in CD activity assessment and MMP-9 in UC, supporting their combined clinical utility.
Downloads
References
Lamb CA, Titterton C, Banerjee R, Gomberg A, Rubin DT, Hart AL. Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care. The Lancet. 2024;404(10451):414-417. doi:10.1016/S0140-6736(24)00983-8
Lin D, Jin Y, Shao X, et al. Global, regional, and national burden of inflammatory bowel disease, 1990–2021: Insights from the global burden of disease 2021. Int J Colorectal Dis. 2024;39(1):139. doi:10.1007/s00384-024-04711-x
Alsakarneh S, Ahmed M, Jaber F, et al. Inflammatory bowel disease burden in the Middle East and North Africa Region: a comprehensive analysis of incidence, prevalence, and mortality from 1990-2019. Ann Gastroenterol. 2024;37(5):527. doi:10.20524/aog.2024.0898
Vindigni SM, Zisman TL, Suskind DL, Damman CJ. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol. 2016;9(4):606-625. doi:10.1177/1756283X16644242
Stolfi C, Maresca C, Monteleone G, Laudisi F. Implication of intestinal barrier dysfunction in gut dysbiosis and diseases. Biomedicines. 2022;10(2):289. doi:10.3390/biomedicines10020289
Soubières AA, Poullis A. Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7(1):41. doi:10.4292/wjgpt.v7.i1.41
Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817-1826.e2. doi:10.1053/j.gastro.2010.11.058
Costa F, Mumolo M, Bellini Ma, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35(9):642-647. doi:10.1016/s1590-8658(03)00381-5
Yang Y, Fu K-Z, Pan G. Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis. World J Gastrointest Surg. 2024;16(1):228. doi:10.4240/wjgs.v16.i1.228
Richards CD. The enigmatic cytokine oncostatin m and roles in disease. Int Sch Res Notices. 2013;2013(1):512103. doi:10.1155/2013/512103
West NR, Hegazy AN, Owens BM, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579-589. doi:10.1038/nm.4307
Verstockt S, Verstockt B, Machiels K, et al. Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(10):1564-1575. doi:10.1093/ibd/izab032
Guo A, Ross C, Chande N, et al. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists. Sci Rep. 2022;12(1):1185. doi:10.1038/s41598-022-05208-9
O’Sullivan S, Gilmer JF, Medina C. Matrix metalloproteinases in inflammatory bowel disease: an update. Mediators Inflamm. 2015;2015(1):964131. doi:10.1155/2015/964131
Yabluchanskiy A, Ma Y, Iyer RP, Hall ME, Lindsey ML. Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda). 2013;28(6):391-403. doi:10.1152/physiol.00029.2013
Al-Sadi R, Engers J, Haque M, King S, Al-Omari D, Ma TY. Matrix Metalloproteinase-9 (MMP-9) induced disruption of intestinal epithelial tight junction barrier is mediated by NF-κB activation. PLoS One. 2021;16(4):e0249544. doi:10.1371/journal.pone.0249544
Nighot P, Al-Sadi R, Rawat M, Guo S, Watterson DM, Ma T. Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis. Am J Physiol Gastrointest Liver Physiol. 2015;309(12):G988-G997. doi:10.1152/ajpgi.00256.2015
Domislovic V, Høg Mortensen J, Lindholm M, et al. Inflammatory biomarkers of extracellular matrix remodeling and disease activity in Crohn’s disease and ulcerative colitis. J Clin Med. 2022;11(19):5907. doi:10.3390/jcm11195907
Ko HS, Park BJ, Choi SK, et al. STAT3 and ERK signaling pathways are implicated in the invasion activity by oncostatin M through induction of matrix metalloproteinases 2 and 9. Yonsei Med J. 2016;57(3):761-768. doi:10.3349/ymj.2016.57.3.761
Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70(3):439-444. doi:10.1016/S0016-5085(76)80163-1
Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2025;120(6):1225-1264. doi:10.14309/ajg.0000000000003465
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317(26):1625-1629. doi:10.1056/NEJM198712243172603
Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;120(6):1187-1224. doi:10.14309/ajg.0000000000003463
Aziz N, Detels R, Quint JJ, Li Q, Gjertson D, Butch AW. Stability of cytokines, chemokines and soluble activation markers in unprocessed blood stored under different conditions. Cytokine. 2016;84:17-24. doi:10.1016/j.cyto.2016.05.010
Tarr G, Williams M, Phillips L, van Rij A, Jones G. Seasonal variation and stability of matrix metalloproteinase-9 activity and tissue inhibitor of matrix metalloproteinase-1 with storage at− 80 C. Clin Biochem. 2011;44(16):1346-1348. doi:10.1016/j.clinbiochem.2011.08.1134
Verstockt S, Verstockt B, Vermeire S. Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD). Expert Opin Ther Targets. 2019;23(11):943-954. doi:10.1080/14728222.2019.1677608
Karwi YG, Arif IS, Abdulameer SA. Evaluating serum calprotectin and serum oncostatin M levels as diagnostic markers in Crohn's disease and ulcerative colitis in Iraqi patients. Al Mustansiriyah J Pharm Sci. 2024;24(2):217-227.
Saleh HH, Khadim DJ, Hussein RJ. Correlation between therapeutic drug monitoring of infliximab serum trough levels and other iomarkers in Iraqi patients with Crohn's Disease. Al-Rafidain J Med Sci. 2024;6(1):239-245.
Wolf CL, Pruett C, Lighter D, Jorcyk CL. The clinical relevance of OSM in inflammatory diseases: a comprehensive review. Front Immunol. 2023;14:1239732. doi:10.3389/fimmu.2023.1239732
Khudhur NE, Falih ES, Hachim SK. Association of MMP-9 and PAD-4 according to UC extension and severity. Perinat J. 2026;34(1):616-624.
Al-Abassi HM, Nazal MF, Ad'hiah AH, et al. Serum profile of cytokines in Iraqi inflammatory bowel disease patients. Mustansiriya Med J. 2015;14(2):11-16.
Derkacz A, Olczyk P, Olczyk K, Komosinska-Vassev K. The role of extracellular matrix components in inflammatory bowel diseases. J Clin Med. 2021;10(5):1122. doi:10.3390/jcm10051122
Siloşi I, Boldeanu MV, Mogoantă SŞ, et al. Matrix metalloproteinases (MMP-3 and MMP-9) implication in the pathogenesis of inflammatory bowel disease (IBD). Rom J Morphol Embryol. 2014;55(4):1317-24.
Garg P, Ravi A, Patel NR, et al. Matrix metalloproteinase-9 regulates MUC-2 expression through its effect on goblet cell differentiation. Gastroenterology. 2007;132(5):1877-1889. doi:10.1053/j.gastro.2007.02.048
Shamseya AM, Hussein WM, Elnely DA, Adel F, Header DA. Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2021;33(1S):e803-e809. doi:10.1097/MEG.0000000000002264
Cao Y, Dai Y, Zhang L, et al. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay. Clin Biochem. 2022;100:35-41. doi:10.1016/j.clinbiochem.2021.11.011
Bertani L, Fornai M, Fornili M, et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther. 2020;52(2):284-291. doi:10.1111/apt.15870
Jucan A-E, Sarbu G-E, Mihai V-C, et al. Serum oncostatin M in ulcerative colitis patients and its relation to disease activity. Int J Mol Sci. 2025;27(1):307.
Ghweil A, Khodeary A, Aziz S. Diagnostic value of fecal calprotectin and serum MMP-9 in diagnosing disease activity of ulcerative colitis. Open J Gastroenterol. 2018;8(06):234.
Yablecovitch D, Kopylov U, Lahat A, et al. Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis. Therap Adv Gastroenterol. 2019;12:1756284819881590. doi:10.1177/1756284819881590
Czajkowska A, Guzinska-Ustymowicz K, Pryczynicz A, Lebensztejn D, Daniluk U. Are matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 useful as markers in diagnostic management of children with newly diagnosed ulcerative colitis? J Clin Med. 2022;11(9):2655. doi:10.3390/jcm11092655
Nagata T, Kai H, Shibata R, Koga M, Yoshimura A, Imaizumi T. Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metalloproteinase-9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23(4):588-593. doi:10.1161/01.ATV.0000060891.31220.23
Goodman WA, Erkkila IP, Pizarro TT. Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(12):740-754. doi:10.1038/s41575-020-0354-0
Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. Therap Adv Gastroenterol. 2020;13:1756284820915043. doi:10.1177/1756284820915043
Matusiewicz M, Neubauer K, Mierzchala-Pasierb M, Gamian A, Krzystek-Korpacka M. Matrix metalloproteinase‐9: its interplay with angiogenic factors in inflammatory bowel diseases. Dis Markers. 2014;2014(1):643645. doi:10.1155/2014/643645
Goffin L, Fagagnini S, Vicari A, et al. Anti-MMP-9 antibody: a promising therapeutic strategy for treatment of inflammatory bowel disease complications with fibrosis. Inflamm Bowel Dis. 2016;22(9):2041-2057.
Mohammed BI, Amin BK. Differential Gene Expression Profiles in Inflammatory Bowel Disease Patients from Kurdistan, Iraq. Sultan Qaboos Univ Med J. 2024;24(1):85.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
